Objective: Open (OPAR) and endovascular (EPAR) repair are both used to treat popliteal artery aneurysm (PAA). We assessed outcomes of both modalities in the treatment of asymptomatic PAAs. Methods: Vascular Quality Initiative (VQI) databases (2010 to 2013) were queried for patients undergoing asymptomatic PAA repair using OPAR and EPAR. The groups were compared with respect to demographics, medical history, and procedural characteristics. Outcomes of interest were length of stay (LOS), major adverse limb events (MALE), MALE or perioperative death (MALE-POD), and loss of primary patency compared using Kaplan-Meier estimates. Proportional hazard Cox regression was used to compare the outcomes across the treatment groups. Multivariable regression with backward elimination procedure (a [ .5) was used to construct parsimonious models to predict MALE and MALE-POD. Gamma regression was used to compare LOS. Results: From 2010 to 2013, 390 patients with asymptomatic PAAs were identified (221 OPAR, 169 EPAR) and included in this study. Preoperative comorbidities were similar between the two groups, except for a higher rate of congestive heart failure (19.5% vs 11.8%, P [ .042) and chronic obstructive pulmonary disease (19.5% vs 11.8%, P [ .042) in the EPAR group. No in-hospital mortality was observed. LOS was significantly longer in the OPAR group (3.8 6 2.5 vs 1.4 6 1.9 days; P < .001). OPAR patients had a significantly higher MALE-free survival (95% vs 80%; P < .001) as was MALE-POD-free survival (93% vs 80%; P < .001) rates at 1 year after the procedure. OPAR was associated with lower hazard of MALE (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.15-0.86; P < .05), MALE-POD (HR, 0.28; 95% CI, 0.13-0.63; P < .05), and primary patency loss (HR, 0.25; 95% CI, 0.10-0.58; P < .05).
Popliteal artery aneurysms (PAAs) are the most common peripheral arterial aneurysms and are associated with significant morbidity. 1 In patients with asymptomatic PAAs, elective repair has been recommended for PAAs >2 cm and for smaller aneurysms if associated with mural thrombus. 1 Current treatment options include open PAA repair (OPAR) using surgical bypass with aneurysm exclusion and endovascular PAA repair (EPAR) using a stent graft.
OPAR has been shown to have excellent graft patency and limb salvage rates 2 but is associated with the need for general or regional anesthesia, a 10% to 20% surgical site infection rate, and other complications such as seroma, hematoma, and neurologic injury. 3 EPAR is a minimally invasive technique that can be performed under conscious sedation but may be associated with a higher risk of graft thrombosis, stent fracture, and may have a lower longterm success rate. 4 Although OPAR has remained the goal standard of therapy, EPAR use has significantly increased over time. 5 Published comparative studies of current PAA management are somewhat conflicting: some authors suggest equipoise of the two treatment options, 6, 7 whereas others advocate advantages of open repair over endovascular repair. 8 Few studies have used different analytic methodologies to directly compare outcomes after OPAR with those after EPAR, [6] [7] [8] [9] [10] [11] [12] and the only published prospective, randomized trial that evaluated outcomes after OPAR and EPAR included just 30 patients. 6 The decision to undertake OPAR or EPAR varies widely among practitioners and is based on a range of factors, including disease pattern, availability of autogenous conduit, surgical and endovascular skill sets, access to an appropriate procedural environment, and practitioner bias.
The paucity of strong comparative data further clouds the decision process. For example, most single or even multicenter trials include symptomatic and asymptomatic patients in their analyses. [7] [8] [9] [10] [11] [12] The inclusion of symptomatic patients with varying degrees of outflow abnormalities introduces a certain degree of bias that renders the interpretation of results difficult.
We set out to compare outcomes in patients with asymptomatic PAAs undergoing OPAR or EPAR using Society of Vascular Surgery (SVS) Objective Performance Guidelines (OPG)-approved limb-specific end points 13 in the Vascular Quality Initiative (VQI). The primary outcomes compared included major adverse limb events (MALE)-free survival, MALE or perioperative death (MALE-POD)-free survival, and loss of primary patency. This report describes the comparison of outcomes after OPAR vs EPAR in the multicenter sample of patients who underwent asymptomatic PAA repair.
METHODS
The VQI was launched in 2010 14 based on the success of the Vascular Group of New England (VSGNE). The VQI currently includes 290 centers in 45 states in the United States and Ontario, Canada, and is composed of 16 collaborative regional centers that prospectively collect data on lower extremity peripheral interventions (bypass or endovascular operations). 15 The purpose of the VQI is to "provide benchmark reports" to the participating centers and surgeons to improve the quality of vascular care.
14 Data are prospectively collected by trained nurses or clinical abstractors on >100 clinical and demographic variables. The Boston University School of Medicine Institutional Review Board approved the use of deidentified data for this study, and because this is a deidentified database, no individual patient's consent was required.
The VQI databases (2010 to 2013) for infrainguinal lower extremity bypass (LEB) and peripheral vascular interventions (PVI) were queried to identify patients who underwent repair of asymptomatic PAAs (Fig 1) . These databases collect similar preoperative demographic information about the patients undergoing these procedures. The VQI LEB and PVI databases collect different in-hospital postprocedural complications between the two cohorts during the index admission. Both databases collect detailed data about the index procedure, such as the type of conduit used in LEB or the artery or arteries treated by endovascular interventions. 15 Patients are included in only one database during an index admission.
Outcomes evaluated included MALE-free survival, MALE-POD-free survival, and primary patency loss. MALE was defined as any major limb amputation (above-ankle amputation of the index limb) or reintervention (new bypass graft, jump/interposition graft revision; angioplasty, stent, or stent graft; or thrombectomy/thrombolysis). The MALE end points were adapted from the published OPG guidelines to include minor and major interventions, and the VQI database has been minimally adjusted to track these interventions. 13 POD was defined as death #30 days after the target intervention (OPAR or EPAR). MALE-POD was defined as occurrence of MALE or POD. In the MALE-free survival analysis, the event was defined as MALE or death during 1 year after the target intervention. Postoperative length of stay (LOS) was assessed and compared between the OPAR vs EPAR groups. Subgroup analyses comparing the OPAR group with single-segment great saphenous vein (ssOPAR) with EPAR were also performed.
Summary statistics were generated and assessed for the total sample size. The two cohorts were compared with respect to demographics and medical history to assess the differences between cohorts. Student t-test or gamma regression (continuous variables) and c 2 or Fisher exact test (categoric variables) were used for these bivariate comparisons. For the time to the primary event, KaplanMeier product-limit estimates of the event-free survival time distributions were computed for each treatment group. The groups were compared using the nonparametric log-rank test.
Proportional hazard Cox regression analyses that adjust for the confounding variable were performed. The hazard ratio (HR) and its 95% confidence interval (CI) was estimated in a Cox regression model in which time to the outcome of interest was the dependent variable and the intervention performed (bypass or stent) was the risk variable. The means ratio and corresponding 95% CI was estimated with gamma regression comparing postoperative LOS in the two risk groups. The covariates were selected if different (at 0.1 level) across the groups or clinically important and in both types of multivariable models included age, gender, history of smoking, comorbidities (diabetes, coronary artery disease, cerebrovascular disease, congestive heart failure, history of peripheral vascular disease, and renal disease), and American Society of Anesthesiologists (ASA) Physical Status Classification. Parsimonious models were created after performing the process of backward elimination with a level ¼ 0.5 to stay in the model. P values < .05 were considered statistically significant. Data analyses were performed using SAS 9.3 software (SAS Institute Inc, Cary, NC).
RESULTS
Baseline variables. Between 2010 and 2013, the VQI LEB database included 13,528 patients, and the VQI PVI database included 30,399 patients. By following the algorithm outlined in Fig 1, we included 390 patients with asymptomatic PAAs in this study and identified 169 in the PVI database (EPAR group) and 221 in the LEB database (OPAR group). During this 4-year study period, the annual use of EPAR increased from 34.8% (2010) to 47.6% (2013), although this trend was not significant (test of trend P ¼ .068).
Bivariate comparison of patient cohorts. Table I summarizes the demographics, comorbidities, and medical history of patients treated for asymptomatic PAAs. Patients in the OPAR group were younger, and the proportion of nonsmokers was higher (P < .05). The OPAR group had a higher percentage of women, although this difference did not reach statistical significance (Table I) . Congestive heart failure and chronic obstructive pulmonary disease were significantly less prevalent in the OPAR group (P < .05; Table I ). Most other comorbidities were less prevalent in the OPAR group, but these differences did not achieve statistical significance (Table I) . Preoperative ankle-brachial indices were almost identical between the two cohorts (Table I) .
Patients in the two cohorts differed in the frequency of prior vascular interventions. Prior LEB procedures on the ipsilateral or contralateral limb were significantly higher in the OPAR group (34.8% vs 20.7%; P ¼ .002), whereas coronary vascular interventions were more prevalent in the EPAR group (34.3% vs 20.8%; P ¼ .072). During the index admission, an infection rate of 1.1% was observed in the OPAR group. The most common preprocedural complication in the EPAR group was puncture site hematomas (2.4%). Postoperative myocardial infarction was 0.6% of the OPAR group; these data are not collected in the PVI database (Table I) . Table II describes some of the intraoperative variables and postoperative in-hospital and crude comparison of postoperative hospital LOS. Median hospital LOS was significantly higher in the OPAR group (3.8 6 2.5 days vs 1.4 6 1.9 days; P < .001). The conduits used were singlesegment great saphenous vein in 172 (77.8%), followed by polytetrafluoroethylene in 25 (11.3%). No in-hospital mortality was observed in either group. Similar observations were made between EPAR and ssOPAR cohorts.
The crude comparison of long-term follow-up results showed lower rates of 1-year mortality (1.8% vs 0.5%; P ¼ .32), MALE (6.5% vs 5%; P ¼ .51), and MALE-POD (8.3% vs 5.4%; P ¼ .308) in the OPAR group, but none of these differences were statistically significant. The (Figs 2-4) . Log-rank tests, which provide a method of comparing risk-adjusted events, revealed significantly higher rates of 1-year MALE-free survival (Fig 2) , 1-year MALE-POD-free survival (Fig 3) , and lower rates of 1-year patency loss (Fig 4) in the OPAR group compared with the EPAR group. Log-rank analyses comparison of the ssOPAR subgroup and the EPAR yielded comparable results.
Univariate and adjusted outcome comparisons. unadjusted analysis of outcomes comparing OPAR and EPAR. These analyses suggest a significant difference between the two procedures. Analyses that adjust for the confounding variables (Table III) Fig 5) . None of the other variables included in the adjusted analyses of MALE, MALE-POD, or loss of primary patency was significant at the a ¼ .05 level.
DISCUSSION
In this largest comparison of two procedures to treat asymptomatic PAAs, the EPAR patients were significantly older and had higher frequency of comorbidities. Annual use of EPAR increased by 13% in this sample. LOS was significantly shorter for the EPAR cohort, but MALE-free survival and MALE-POD-free survival were significantly higher for the OPAR patients. The type of procedure was independently predictive of adverse outcomes: endovascular treatment was significantly associated with higher hazards of MALE, MALE-POD, and primary patency loss.
We excluded patients with symptomatic PAAs to decrease any bias related to abnormalities of arterial outflow. Huang et al 8 showed that PAA patients with only zero or one outflow vessel had a significantly higher HR of major adverse events than PAA patients with a normal number of outflow vessels. Although the VQI database does not provide the number of outflow vessels in the OPAR patients, the observation that preoperative anklebrachial indices in the OPAR and EPAR cohorts were within normal reference ranges (Table I) suggests that the analysis is not biased by the quality of arterial outflow between the two cohorts.
The goal of treatment for asymptomatic PAAs is to exclude the PAAs, thereby reducing the risk of thrombosis inherent in PAAs >2.0 cm. 16 OPAR has been shown to be durable, with excellent results.
2,3,17 Dorweiler et al 2 showed a 5-year primary patency rate of 88.1% after OPAR that increased to 92.1% with assistance. Although VQI does not allow for long-term follow-up >1 year, the 1-year primary patency rate in the OPAR group in this study was 95.9% and comparable to the 92.3% rate in EPAR group. The patency rates reported here are similar to others for OPAR 2, 3, 17 and EPAR 4,9,10,18 performed on asymptomatic patients.
As in our study reported here, other studies also report very low in-hospital mortality rates after these operations. In the case of OPAR, the concern is the overall 11% perioperative morbidity rate associated with open repair. 3 Surgical site infection is reported in 2.1% of patients. 3 Because the VQI database is limited to in-hospital data and data collected at the 1-year follow-up, our data cannot ascertain perioperative complications beyond the index hospitalization after either procedure. In our study, the rate of in-hospital infection was 1.1% in the OPAR group. These rates were not recorded in the PVI data of the VQI database. In the EPAR group, puncture site hematoma was the most common complication reported in 2.4% of the cases. Many studies that have compared the outcomes between OPAR and EPAR using different methodologies show similar patency results between the two procedures. 7, 8, 10, 11 Similarly, our analysis showed excellent comparable 1-year primary patency results between the two cohorts. A more valid way of comparing outcomes after two procedures is to compare adverse events using SVS-OPG guidelines. 19 Using these guidelines, for asymptomatic PAA patients, our study showed a significant advantage for the OPAR patients compared with the EPAR cohort. At 1 year, OPAR patients had significantly higher rates of MALE-free and MALE-POD-free survival. Huang et al 8 also observed a similar trend in asymptomatic patients, but the results were not statistically significant, perhaps because they only had 125 elective cases (32 EPAR and 93 OPAR). Similarly, Galinanes et al 5 observed that the rate of reintervention among EPAR patients was significantly higher for Medicaid and Medicare recipients.
There are many limitations of a retrospective analysis using the VQI database. In addition to inherent limitations of any retrospective analysis, certain shortcomings stem from factors inherent to the VQI database. Some of these limitations were discussed previously. The VQI database also does not collect some of the variables that may affect the patency rates; for example, the length and diameter of the bypass graft in the open group is unknown. Similar deficiencies are noted in the PVI database of the VQI, including unknown length of stents, number of stents used, type of stents, and presence of type II endoleak, among others. These deficiencies may lead to comparing groups that are anatomically different from one another.
These variables are all accounted for in the revised forms for the Open vs Endovascular Popliteal Artery Aneurysm Repair (OVERPAR) trial where these variables are collected, allowing for a more meaningful comparison. The most significant issue is that the VQI database collects data only at the time of the index admission and at the 1-year follow-up. 14 This will lead to missing critical perioperative (#30 days postoperative) data needed for a meaningful comparison. VQI also does not collect readmission data, leading to loss of important comparative data. Despite this, the VQI database is a strong tool for comparative analysis.
In 2012, we proposed an intention-to-treat clinical study to the New England Society for Vascular Surgery that would use the VSGNE platform to perform a prospective randomized trial on a very limited budget. We received a $10,000 award to prospectively enroll patients with asymptomatic PAAs, randomize them to either of the therapeutic limbs, and then monitor these patients at 1 month and annually for at least 2 years. Since then, our study has recruited 21 VQI centers and, as such, will be the largest multicenter trial of patients with asymptomatic PAAs that will provide level I data using VQI machinery. 20 This study is appropriately powered to definitely answer if one procedure is superior to the other. 20 To overcome some of the missing variables in the VQI database, new fields have been added to the VQI data entry fields for the OVERPAR patients to address missing relevant questions that are currently lacking in standard VQI forms. 20 The OVER-PAR trial participants will also receive quality of life surveys at each clinic visit to compare their satisfaction with these treatments. 20 Despite the limitations noted here, our study suggests that OPAR leads to superior outcomes compared with EPAR among asymptomatic PAA patients.
CONCLUSIONS
This study comprises the largest comparative analysis among asymptomatic patients with PAAs. Despite the limitations noted, our results indicate that patients who underwent OPAR had significantly less 1-year rates of adverse outcomes. This suggests that OPAR should be preferentially offered to patients who can tolerate either therapeutic option. We believe that ultimately the ongoing prospective randomized OVERPAR trial will definitively answer if one procedure is superior to the other while overcoming some of the limitations noted here.
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